دورية أكاديمية
The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review.
| العنوان: | The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review. |
|---|---|
| المؤلفون: | Baniaamam M; a Amsterdam Rheumatology Immunology Center , Amsterdam , the Netherlands.; b Department of Rheumatology , Jan van Breemen Research Institute/Reade , Amsterdam , the Netherlands.; c Amsterdam Cardiovascular Sciences , VUmc/Reade/AMC/Sanquin , Amsterdam , the Netherlands., Paulus WJ; d Department of Physiology , VU University Medical Center , Amsterdam , the Netherlands., Blanken AB; a Amsterdam Rheumatology Immunology Center , Amsterdam , the Netherlands.; b Department of Rheumatology , Jan van Breemen Research Institute/Reade , Amsterdam , the Netherlands., Nurmohamed MT; a Amsterdam Rheumatology Immunology Center , Amsterdam , the Netherlands.; b Department of Rheumatology , Jan van Breemen Research Institute/Reade , Amsterdam , the Netherlands.; e Department of Rheumatology , VU University Medical Center , Amsterdam , the Netherlands. |
| المصدر: | Expert opinion on biological therapy [Expert Opin Biol Ther] 2018 May; Vol. 18 (5), pp. 585-594. Date of Electronic Publication: 2018 Apr 23. |
| نوع المنشور: | Journal Article; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Ashley Publications Ltd., c2001- |
| مواضيع طبية MeSH: | Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Biological Products/*therapeutic use , Heart Failure/*prevention & control, Arthritis, Rheumatoid/complications ; Heart Failure/epidemiology ; Humans ; Inflammation/complications ; Inflammation/drug therapy |
| مستخلص: | Introduction: A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA. Areas Covered: Observational cohort, randomized controlled trials and case-controlled studies were included. The systematic literature search was conducted in PubMed, Wiley/Embase, Cochrane, Web of Science and clinicaltrials.gov (up to 2017). Two authors assessed abstracts for inclusion and methodological quality was assessed by one reviewer. Expert Opinion: RA patients have a clinically relevant increased risk of developing CHF needing further attention. However, we found a lack of high quality studies. Future studies should focus on distinguishing the effect of myocardial inflammation reduction versus antibody-specific myocardial cellular effects of bDMARDs to improve the understanding of the effects of bDMARDs in RA patients and the relation with the development of CHF. |
| فهرسة مساهمة: | Keywords: Congestive heart failure; NT-proBNP; bDMARDs; cardiac function; cardiac imaging; incidence/prevalence; inflammation; rheumatoid arthritis |
| المشرفين على المادة: | 0 (Antirheumatic Agents) 0 (Biological Products) |
| تواريخ الأحداث: | Date Created: 20180407 Date Completed: 20190111 Latest Revision: 20190417 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1080/14712598.2018.1462794 |
| PMID: | 29623726 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-7682 |
|---|---|
| DOI: | 10.1080/14712598.2018.1462794 |